Login with ORCID

assertion

Full identifier: http://purl.org/np/RAIm6t-GCskebgwkveeYnpaHe8C5_V_BzvdoIiWDB9NDs#assertion

Minted in Nanopublication

 RAIm6t-GCs comment approve/disapprove edit as derived nanopublication

This is a local identifier minted within the nanopublication. http://purl.org/np/RAIm6t-GCs...#sig
sig
http://purl.org/nanopub/x/hasSignatureTarget has as target This is the identifier for this whole nanopublication. http://purl.org/np/RAIm6t-GCs... this nanopublication .
This is a local identifier minted within the nanopublication. http://purl.org/np/RAIm6t-GCs...#sig
sig
http://purl.org/nanopub/x/hasAlgorithm has the algorithm (this is a literal)
.

References

Nanopublication Part Subject Predicate Object Published By Published On
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
assertion
Elif Ozkan
2022-10-10T15:19:49.777Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
assertion
2022-10-10T15:19:49.777614
Elif Ozkan
2022-10-10T15:19:49.777Z
links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance
assertion
Fluticasone Furoate/Vilanterol ELLIPTA 100/25 mcg is indicated for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. The drug is NOT indicated for relief of acute bronchospasm.
Elif Ozkan
2022-10-10T15:19:49.777Z

Raw

TriG(txt), JSON-LD(txt), N-Quads(txt), XML(txt)